Loading organizations...
DeepKinase is a China-based biotechnology company that commercializes a proprietary proteomics platform technology designed to address unmet clinical needs within the global oncology sector. The organization leverages specialized expertise in functional genomics, advanced proteomics, and complex cancer mechanisms to develop precise diagnostic and therapeutic tools for various clinical applications. Operating primarily within the clinical diagnostics market, the enterprise focuses on translating deep industry insights into scalable solutions for cancer-related medical challenges. The executive leadership team draws on prior biotechnology industry experience from recognizable organizations such as MegaGenomics to guide the company's strategic commercialization efforts. In 2022, the firm expanded its scientific leadership by appointing Dr. Liu as Chief Research Officer to further advance its proprietary platform development. DeepKinase was founded in 2019 by chief executive officer Nelson Naizhong Zheng alongside co-founders Shawn Shun-Cheng Li and Yun Xiao.
DeepKinase has raised $14.2M across 1 funding round.
DeepKinase has raised $14.2M in total across 1 funding round.
DeepKinase has raised $14.2M across 1 funding round. Most recently, it raised $14.2M Series A Extension in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 25, 2023 | $14.2M Series A Plus | Zhihua YU | Feifan Venture Capital, Fengrui Capital, Zhongguancun Development Group | Announced |
DeepKinase has raised $14.2M in total across 1 funding round.
DeepKinase's investors include Zhihua Yu, Feifan Venture Capital, Fengrui Capital, Zhongguancun Development Group.
